GLI1 and cancer: This non‐canonical, Hh ligand‐ and Smo‐independent activation of GLI explains the higher aggressiveness of cancers harboring non‐canonical Hh signaling and the acquired resistance to Smo inhibitors in cancer therapy.[29] These findings prompted us to investigate whether GLI2 activity is also regulated by matrix stiffness.